How big is HCW Biologics Inc.?

As of Jun 18, HCW Biologics Inc. has a market capitalization of 12.79 million, with net sales of 1.45 million and a net profit of -24.75 million over the last four quarters. The company reported shareholder's funds of -6.77 million and total assets of 30.24 million as of Dec 24.

Market Cap: As of Jun 18, HCW Biologics Inc. has a market capitalization of 12.79 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, HCW Biologics Inc. reported net sales of 1.45 million and a net profit of -24.75 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -6.77 million and total assets of 30.24 million.

What does HCW Biologics Inc. do?

HCW Biologics Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $2 million as of March 2025. The company has a market cap of $12.79 million and does not pay dividends.

Overview:<BR>HCW Biologics Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 12.79 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.50 <BR>Return on Equity: 160.02% <BR>Price to Book: -1.49 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold HCW Biologics Inc.?

Is HCW Biologics Inc. overvalued or undervalued?

As of August 14, 2025, HCW Biologics Inc. is considered overvalued and not a viable investment due to its negative valuation ratios and a year-to-date decline of 74.56%, contrasting sharply with the positive performance of the S&P 500.

As of 14 August 2025, the valuation grade for HCW Biologics Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its negative valuation ratios, including a Price to Book Value of -1.70, an EV to EBIT of -2.12, and an EV to EBITDA of -2.38. These metrics suggest that the company's financial performance is not only poor but also unsustainable compared to its peers.<BR><BR>In comparison to its industry, HCW Biologics Inc. shows a stark contrast with peers like Elicio Therapeutics, Inc., which has an EV to EBITDA of -4.1277, and Eliem Therapeutics, Inc., with an EV to EBITDA of -1.5652. The company's returns have been dismal, with a year-to-date decline of -74.56% compared to a positive return of 12.22% for the S&P 500, further reinforcing the notion that HCW Biologics is not a viable investment at this time.

Is HCW Biologics Inc. technically bullish or bearish?

As of August 25, 2025, HCW Biologics Inc. shows a mildly bearish trend with mixed technical indicators, including mildly bullish MACD readings but significant underperformance of -81.08% compared to the S&P 500's 17.14%.

As of 25 August 2025, the technical trend for HCW Biologics Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, and both the weekly and monthly Bollinger Bands are bearish, suggesting continued pressure on the price. The KST shows a mixed signal with weekly mildly bullish and monthly bearish readings, and the OBV indicates a bullish stance on the monthly timeframe but no trend on the weekly. <BR><BR>In terms of performance, HCW Biologics has significantly underperformed the S&P 500 over the past year, with a return of -81.08% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by mixed indicators and significant underperformance relative to the benchmark.